Abstract
In eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes opposite, functions from a given gene. Angiogenesis is the process of vascularisation in physiological conditions and a series of pathologies, including cancer where it favours tumour progression and dissemination of metastasis. In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the molecular mechanisms that trigger alternative splicing toward one or the other direction start to be elucidated. The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.
Keywords: Alternative splicing, angiogenesis, small molecules angiogenesis inhibitors, VEGF, VEGF111, constitutive splicing, isoforms, SRPK, ischemia, hypertension, preeclampsia, Denys-Drash syndrome, ELISA, Neuropilins, RTKs, metalloproteinase-17, semaphorins, plexin-1, Sema3A, Tie-2, Ang-2, VASH1, SULF-1, CAM assay, SDF-1, CXCR4, CXCR7, Neuregulin-2, Fibronectin, Migration-stimulating factor, MSF, CD44, PECAM-1/CD31, MAPK/ERK, HYAL-1, Hyaluronidase-1, TrpRS, Signalling Molecules, KLF6, camptothecin, doxorubicin, cis-platinum, Epigallocatechin gallate, Duch-ene muscular dystrophy, HDAC, Topoisomerase I, Topoisomerase II, CLK kinases, GSK3, Protein phosphatase 1, cAMP pathway, Transcription-splicing coupling, cystic fibrosis
Current Pharmaceutical Design
Title: Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Volume: 16 Issue: 35
Author(s): Carine Munaut, Alain C. Colige and Charles A. Lambert
Affiliation:
Keywords: Alternative splicing, angiogenesis, small molecules angiogenesis inhibitors, VEGF, VEGF111, constitutive splicing, isoforms, SRPK, ischemia, hypertension, preeclampsia, Denys-Drash syndrome, ELISA, Neuropilins, RTKs, metalloproteinase-17, semaphorins, plexin-1, Sema3A, Tie-2, Ang-2, VASH1, SULF-1, CAM assay, SDF-1, CXCR4, CXCR7, Neuregulin-2, Fibronectin, Migration-stimulating factor, MSF, CD44, PECAM-1/CD31, MAPK/ERK, HYAL-1, Hyaluronidase-1, TrpRS, Signalling Molecules, KLF6, camptothecin, doxorubicin, cis-platinum, Epigallocatechin gallate, Duch-ene muscular dystrophy, HDAC, Topoisomerase I, Topoisomerase II, CLK kinases, GSK3, Protein phosphatase 1, cAMP pathway, Transcription-splicing coupling, cystic fibrosis
Abstract: In eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes opposite, functions from a given gene. Angiogenesis is the process of vascularisation in physiological conditions and a series of pathologies, including cancer where it favours tumour progression and dissemination of metastasis. In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the molecular mechanisms that trigger alternative splicing toward one or the other direction start to be elucidated. The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.
Export Options
About this article
Cite this article as:
Munaut Carine, C. Colige Alain and A. Lambert Charles, Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455012
DOI https://dx.doi.org/10.2174/138161210794455012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Current Cancer Drug Targets A Sialic Acid-Specific Lectin from the Mushroom Paecilomyces Japonica that Exhibits Hemagglutination Activity and Cytotoxicity
Protein & Peptide Letters Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges
Current Drug Safety Mevalonate Cascade and Small Rho GTPase in Spinal Cord Injury
Current Molecular Pharmacology Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry A Brief Evaluation of Tumor Imaging in Mice with 99mTc-glucarate Including a Comparison with 18F-FDG
Current Radiopharmaceuticals Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Recurrent Left Atrial Low-grade Malignant Inflammatory Myofibroblastic Tumor Characterized by Cardiovascular Magnetic Resonance
Current Medical Imaging VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry p53: Fighting Cancer
Current Cancer Drug Targets Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Lung Cancer Epidemiology - A Global View
Current Respiratory Medicine Reviews The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Proteomics as a Tool in the Pharmaceutical Drug Design Process
Current Pharmaceutical Design Overview of Cantharidin and its Analogues
Current Medicinal Chemistry